Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated(ALIVE) | unknown | Phase 3 | 315 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT04287660 | Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | unknown | Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER |
| 1 |
| Oct 25, 2021 |
| clinicaltrials |
| NCT00942357 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | unknown | Phase 3 | 813 | Gynecologic Oncology GroupNETWORK | 3 | Oct 19, 2021 | clinicaltrials |
| NCT05079438 | Dendrobium Huoshanense Suppository in Rectal Cancer | unknown | Phase 3 | 168 | Zhejiang Cancer HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03257241 | A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old(PALG-AML1/2016) | unknown | Phase 3 | 582 | Polish Adult Leukemia GroupOTHER | 2 | Oct 1, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | unknown | Phase 2 / Phase 3 | 469 | Gynecologic Oncology GroupNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT04781270 | mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases | unknown | Phase 3 | 308 | Fudan UniversityOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02242929 | Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma(SCIN) | unknown | Phase 3 | 145 | Maastricht University Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05056337 | Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | unknown | Phase 3 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT05049681 | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | unknown | Phase 3 | 234 | Feng WangOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT04426955 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT05046262 | Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept Study | unknown | Phase 3 | 25 | Bispebjerg HospitalOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04612439 | Accuracy of VABB Elite 10G Versus BARD 14G CNB | unknown | Phase 3 | 1,470 | Fudan UniversityOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)(APL16) | unknown | Phase 3 | 110 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02512315 | A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 192 | Sun Yat-sen UniversityOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04679064 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment(NItCHE-MITO33) | unknown | Phase 3 | 427 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT02631239 | MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma | unknown | Phase 3 | 256 | Ruijin HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT05002686 | Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | unknown | Phase 2 / Phase 3 | 60 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04964479 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 375 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 20, 2021 | clinicaltrials |
| NCT00651261 | Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | unknown | Phase 3 | 717 | Alliance for Clinical Trials in OncologyOTHER | 2 | Aug 18, 2021 | clinicaltrials |
| NCT00003337 | Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma | unknown | Phase 3 | 100 | Gilead SciencesINDUSTRY | 5 | Aug 16, 2021 | clinicaltrials |
| NCT00003338 | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | unknown | Phase 2 / Phase 3 | 60 | Gilead SciencesINDUSTRY | 5 | Aug 16, 2021 | clinicaltrials |
| NCT05006469 | Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 10 | Liao AijunOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04910594 | Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma | unknown | Phase 3 | 130 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04885270 | Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer | unknown | Phase 3 | 50 | West China Second University HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04999176 | Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin(VALERIA) | unknown | Phase 3 | 440 | André Luiz Malavasi Longo de OliveiraOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04741880 | Evaluation of Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia (ELSA Trial)(ELSA) | unknown | Phase 2 / Phase 3 | 66 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04980859 | Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation | unknown | Phase 3 | 45 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jul 28, 2021 | clinicaltrials |
| NCT02448797 | Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation(EVIDENCE) | unknown | Phase 3 | 320 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04047758 | Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer | unknown | Phase 3 | 420 | Shengjing HospitalOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04968002 | Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04358354 | Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer | unknown | Phase 3 | 388 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT02533271 | Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer(STELLAR) | unknown | Phase 3 | 600 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT04961970 | HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03538171 | Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer | unknown | Phase 3 | 375 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03580395 | Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer | unknown | Phase 2 / Phase 3 | 200 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT04951648 | A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation | unknown | Phase 3 | 220 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04939194 | Fast Track Protocol After Radical Cystectomy and Urinary Diversion: A Randomised Controlled Trial. | unknown | Phase 3 | 200 | Mansoura UniversityOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT04933357 | Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy (MART) | unknown | Phase 2 / Phase 3 | 75 | National Cancer Institute, EgyptOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT03720041 | Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma(FiTNEss) | unknown | Phase 3 | 740 | University of LeedsOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT01611766 | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? | unknown | Phase 3 | 356 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 10, 2021 | clinicaltrials |
| NCT04917289 | CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer Patients | unknown | Phase 3 | 100 | Fudan UniversityOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT03927456 | A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | unknown | Phase 3 | 357 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 3, 2021 | clinicaltrials |
| NCT04912258 | Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis | unknown | Phase 3 | 80 | Fudan UniversityOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT03709316 | A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | unknown | Phase 3 | 384 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT03966898 | A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | unknown | Phase 3 | 426 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 2, 2021source: clinicaltrials